A*STAR Bioinformatics Institute (A*STAR BII)

Through close collaborations across scientific disciplines, A*STAR drives new discoveries in neurometabolism and its potential therapeutic applications.

Researchers develop a protocol to boost the effectiveness of and reduce the risk of potential side effects for T cell cancer therapies.

By exploring the genetic diversity within Escherichia coli bacteria, researchers uncover distinct gene families and a molecular weapon tied to disease-causing strains.

Researchers identify an unexpected synergy between bacterial and viral molecules that causes severe inflammation in some patients with COVID-19.

Inactivated COVID-19 vaccines could be an equally potent alternative for people with allergic sensitivities to mRNA-based vaccines.

As Sir David and Birgit Lane leave Singapore, A*STAR Research commemorates the legacy that the couple continues to build for their students, colleagues and the nation’s wider research ecosystem.

Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.

Researchers develop machine learning models for accurately diagnosing an inflammatory skin condition.

Despite the hype, State-of-the-art machine learning challenges one of the toughest problems in systems biology.

To tackle the monumental challenges of the 21st century, the National Supercomputing Centre (NSCC) Singapore brings cutting-edge supercomputing resources to researchers across A*STAR and beyond.

Molecular simulations uncover a new druggable pocket in SARS-CoV-2’s spike protein which could hold the key to blocking COVID-19 infections.

A new polymer gel may offer a drug-free solution to preventing retinal scarring after eye surgery.